Literature DB >> 19015647

Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus.

Konstantinos Tziomalos1, Vasilios G Athyros, Dimitri P Mikhailidis.   

Abstract

Entities:  

Year:  2008        PMID： 19015647     DOI： 10.1038/ncpendmet1021

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN： 1745-8366


× No keyword cloud information.
  6 in total

Review 1.  The 'forgotten' bile acid sequestrants: is now a good time to remember?

Authors:  Harold E Bays; Ronald B Goldberg
Journal:  Am J Ther       Date:  2007 Nov-Dec       Impact factor: 2.688

2.  Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.

Authors:  Ronald B Goldberg; Vivian A Fonseca; Kenneth E Truitt; Michael R Jones
Journal:  Arch Intern Med       Date:  2008-07-28

Review 3.  Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.

Authors:  M Florentin; E N Liberopoulos; D P Mikhailidis; M S Elisaf
Journal:  Curr Med Res Opin       Date:  2008-02-19       Impact factor: 2.580

Review 4.  The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review.

Authors:  Michael H Davidson
Journal:  Expert Opin Pharmacother       Date:  2007-10       Impact factor: 3.889

5.  Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.

Authors:  Nadeem Sarwar; John Danesh; Gudny Eiriksdottir; Gunnar Sigurdsson; Nick Wareham; Sheila Bingham; S Matthijs Boekholdt; Kay-Tee Khaw; Vilmundur Gudnason
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

6.  Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.

Authors:  Vivian A Fonseca; Julio Rosenstock; Antonia C Wang; Kenneth E Truitt; Michael R Jones
Journal:  Diabetes Care       Date:  2008-05-05       Impact factor: 19.112
  6 in total
  2 in total

1.  Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

2.  Repurposing paclitaxel for the treatment of fibrosis: indication discovery for existing drugs.

Authors:  Xiao-Wu Chen; Wei Duan; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-09-07       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.